Federal drug-pricing reforms continue to generate headlines, but the bigger story is how those changes are beginning to influence the broader pharmacy ecosystem. Understanding that landscape can help employers recognize emerging trends and better understand how market changes may eventually affect their health and benefit plans.
What’s Changing?
Federal drug-pricing reform is taking shape through a combination of federal oversight, transparency requirements, reimbursement changes, and state-level legislation. While many of these changes target pharmacy benefit managers (PBMs) and government programs, their influence extends across the pharmacy landscape and can ultimately affect employer-sponsored health plans.
Several developments are contributing to this shift:
The Federal Trade Commission (FTC) filed suit against the three major pharmacy benefit managers (PBMs) and their affiliated purchasing organizations: Caremark/CVS, Express Scripts, and OptumRx. Settlements with Express Scripts and Caremark/CVS included changes related to rebate pass-through, spread pricing, PBM reporting, pricing transparency, support for community pharmacies, and U.S.-based operations (specific to GPO and Rebate aggregation entities).
The Consolidated Appropriations Act of 2026 (CAA 2026) and the proposed Department of Labor (DOL) disclosure rules continue efforts to increase PBM transparency, audit rights, compensation oversight, advance fee disclosures, rebate pass-through requirements, and structural delinking.
Federal policy initiatives, including Trump Rx, Most Favored Nation (MFN) pricing, tariff impacts, and the recent Customs and Border Patrol (CBP) crackdown on drug importation, continue to influence discussion around prescription drug costs. While the long-term impact remains difficult to measure, these initiatives may contribute to changes across the broader pharmacy landscape.
At the state level, approximately 1,600 PBM-related bills were introduced across 46 states in 2026. Many focus on spread pricing bans, vertical integration, rebate pass-through mandates, and PBM compensation structures.
Together, these developments reflect increased scrutiny of drug pricing, greater transparency expectations, and continued evolution in how pharmacy benefits are managed.
Why These Changes Matter to Employees
Employers and other stakeholders are already feeling the impact of these changes, even if they are not always immediately visible.
Many of these reforms focus on government programs, PBMs, and other market participants. However, the effects can extend into employer-sponsored health plans through changes in pricing methodologies, reporting practices, reimbursement models, and benefit administration.
For employers, the biggest shift may not come from the policies themselves, but from how stakeholders interpret and implement those changes across the market. As stakeholders adapt to new requirements and expectations, employers may begin to see changes in how pharmacy benefits are delivered and reported.
This is why awareness matters. Employers do not need to react to every regulatory development. Understanding how the market is evolving can help distinguish proactive decision-making from reactive responses. In a shifting landscape, visibility becomes a meaningful advantage.
How the Market is Responding
The market is responding through greater scrutiny of PBM contracts, more detailed disclosure of fees and rebate arrangements, expanded audit provisions, and growing interest in alternative pricing and pass-through models.
As PBMs adjust their offerings and reporting practices, employers may encounter revised guarantees and more complex contract terms. They may also see new opportunities to compare reported savings with actual plan performance. These shifts make the early signals below increasingly important to monitor.
Early Signals to Watch For
- Drug cost reporting is changing and evolving
- Hidden rebates and fees are being disclosed
- Benefit explanations are becoming more complex
- Gaps between expected and actual plan performance
Key Takeaways
As federal drug-pricing reforms continue to evolve, their full impact on employer-sponsored health plans is still taking shape. While many of these changes may not be immediately visible, staying aware of market developments, industry responses, and emerging trends can help employers better understand what may lie ahead.
Employers should enter 2027 expecting increased oversight of PBM compensation, rebate practices, pricing models, and disclosures. These are all great improvements.
Key priorities include:
- Reviewing PBM contracts for pass-through and audit provisions
- Assessing the member impact of point-of-sale rebates
- Tracking federal implementation timelines
- Monitoring policy-driven supply and pricing changes
- Evaluating state-specific compliance obligations
A coordinated review involving benefits, legal, finance, and procurement teams can help identify cost exposure and necessary contract changes before renewal.
